NEW YORK, November 13, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Horizon Pharma, Inc. (NASDAQ: HZNP), and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Keryx Biopharmaceuticals Inc. Research Report
On November 8, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced preliminary, unaudited data from its ongoing 48-week safety extension study of Zerenex (ferric citrate coordination complex) - Keryx's drug candidate for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. The Company stated that the data demonstrated Zerenex's ability to significantly reduce the need for IV iron and ESAs, while maintaining hemoglobin in dialysis patients. Ron Bentsur, the Company's CEO, commented, "While preliminary, I believe that the data from this OLE study to date reinforces the data observed in the long-term Phase 3 study. Importantly, it is encouraging to see that Zerenex appears to be safe and well tolerated for up to two years of cumulative exposure in clinical studies." The Company informed that its New Drug Application for the use of Zerenex is currently under FDA review with an assigned Prescription Drug User Fee Act goal date of June 7, 2014. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Raptor Pharmaceuticals Corp. Research Report
On November 7, 2013, Raptor Pharmaceuticals Corp. (Raptor Pharmaceuticals) reported its Q3 2013 financial results and provided updates on PROCYSBI(R) launch. PROCYSBI net product sales were reported at $6.6 million. Net loss for the quarter totaled $17.3 million or $0.29 per share compared to net loss of $10.2 million or $0.21 per share in Q3 2012. Christopher M. Starr, Ph.D., Raptor's CEO commented, "With the first full quarter of PROCYSBI sales now complete, I am very pleased with the pace of the launch and our team's performance. We continue to make significant strides in providing access to PROCYSBI and communicating its benefits to both caregivers and patients, which bodes well for our future success. Beyond cystinosis, our Phase 2/3 trial in Huntington's disease is progressing well and we expect to have top-line data in the first quarter of 2014, followed up by full enrollment of our pediatric non-alcoholic fatty liver disease trial." The Company stated that data from its Phase 2/3 study of PROCYSBI (RP103) in Huntington's disease following the first 18 months of treatment are anticipated in Q1 2014. The Full Research Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Pacira Pharmaceuticals Inc. Research Report
On November 8, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced its President and CEO, David Stack is scheduled to present at the Jefferies 2012 Global Healthcare Conference in London on November 15, 2013 at 9:20 a.m. GMT (4:20 a.m. ET). Pacira stated that Mr. Stack is expected to present an overview of the Company. Pacira informed that a live audio webcast of the presentation can be accessed at the Company's website, and its replay will be archived for two weeks after the presentation date on the same location. The Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Horizon Pharma, Inc. Research Report
On November 8, 2013, Horizon Pharma, Inc. (Horizon Pharma) reported its Q3 2013 financial results with net sales of $26.2 million, up 302.1% YoY. Net sales of Duexis and Rayos for the quarter totaled $23.5 million and $2 million respectively, up 122% and 268% YoY. According to the Company, the increase in DUEXIS sales during the Q3 2013 compared to Q3 2012 was primarily the result of the Company's expanded sales force in addition to product price increases implemented during the course of 2013. Net loss for the quarter was $5.5 million or $0.08 per share compared to $17 million or $0.47 per share in Q3 2012. Timothy P. Walbert, Chairman, President and CEO, Horizon Pharma stated, "We achieved continued acceleration in prescriptions and revenue in the third quarter, with both DUEXIS and RAYOS seeing significant growth in net revenue on a sequential quarter over quarter basis. This sales growth, along with improvement in the bottom line and cash burn, continues our momentum toward becoming a profitable company." The Full Research Report on Horizon Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Impax Laboratories Inc. Research Report
On November 7, 2013, Impax Laboratories, Inc. (Impax) announced its scheduled presentation at the Credit Suisse Healthcare Conference which will be held in Scottsdale, Arizona. The Company stated that it will present on Thursday, November 14, 2013 at 9:30 a.m. MST at the conference and a live audio webcast and archived presentation made at the conference will be available at the Company's website under the investor relations section. The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner